Mr. Ravi Rajagopal, aged about 67 years, has been Chairman of Fortis Healthcare since 2018. Mr. Rajagopal led the newly nominated Board in overhauling the governance processes and strengthening the controls.
Mr. Rajagopal is Vice Chairman and Independent Director of The Peabody Group, the UK’s largest affordable housing company. He is a Director and Audit Chair of Airtel Africa Plc, A FTSE 100 company in the UK. He is a Trustee of the Science Museum Foundation UK, the most iconic Museum of its kind in the world. Earlier board experience includes serving as Director and Audit Chair of globally diversified natural resources company, Vedanta plc ( FTSE 250 ) and a Diageo nominee Director of United Spirits, India from 2013 to 2016.
With an extensive career spanning 35 years working in large consumer goods companies, spending the last 20 years with Diageo plc in a variety of senior leadership roles including group controller for the plc and latterly as global head of mergers and acquisitions. Prior to that Mr. Rajagopal was with ITC India across different businesses in India and overseas where he held a number of progressively senior roles. His overall experience includes working in many markets across the world in both a strategic and operational capacity.
Mr. Rajagopal is involved with a number of charitable activities. He is Chair of an Advisory Board for a project responsible for building and operating over 8000 childcare centres across northern India; and he is a Trustee of a group of four schools in Chennai that educates over 1,100 underprivileged children at no cost.
Mr. Rajagopal is a Chartered and Cost Accountant, he has lived in London since 1998. He has lectured on Behavioural Economics at the Saïd Business School, Oxford University and Imperial College, London.
Dr Ashutosh Raghuvanshi, is a cardiac surgeon turned management leader. After completing his MS in general surgery from MGIMS, Dr Ashutosh went on to do MCH in Cardiac surgery from the University of Bombay. Over the last 26 years, he has been associated with the Bombay Hospital, Apollo Hospitals, Vijaya Heart foundation and Manipal Heart Foundation. He is credited with the establishment of Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, where he joined as Director in 2000 and is today one of the largest Multispecialty Hospitals in Eastern India.
Before joining Fortis, he was last working with Narayana Health as Vice Chairman, Managing Director & Group CEO and was responsible for the operations of all the group hospitals across India and internationally.
Over 24 years of leadership experience in various multinational organisations across both financial and healthcare institutions. Self-motivated leader with a variety of skillsets in areas such as investor relations, capital raising, corporate finance, strategy & business development, change management, mergers & acquisitions, financial reporting, revenue cycle management, group procurement and healthcare operations. Results-driven leader, team player and someone who constantly seeks to learn.
Dr. Farid re-joined Khazanah in December 2018 after serving as Chief Strategy Officer of UEM Group. Prior to that, he was with Telekom Malaysia from 2012 to 2017. Dr. Farid first joined Khazanah in July 2004 and stayed until 2011. He was previously a consultant at McKinsey & Co. He holds a Bachelor’s and Master’s degree in Chemical Engineering, as well as PhD in Chemical Engineering, all three from the University of Cambridge.
lndrajit Banerjee, aged about 66 years, is a Chartered Accountant and has a corporate career spanning over 35 years. Over the last 20 years of his corporate career he played a key role in senior leadership positions, principally in Ranbaxy, Cairn India, Lupin and Indian Aluminiuim (Indal), dealing with unique business criticalities which led to the organisations realising their potential values.
He has a B. Com. (Hons) degree from St. Xavier's College, Kolkata. In his early career at Brooke Bond India Ltd and Indal, his focus was on establishing sound financial management systems in complicated business environment which also facilitated businesses to improve their competitive position. Since then, he has played the role of CFO/Executive Director in companies that experienced difficult business situations of varying nature in complex shareholding situations.
Between 1982 and 1999 he was at Indal, of which the final two years he was Chief Financial Officer, where he played a key role in the strategy formation and risk management in the company during the transformation stage. He joined Lupin Ltd in 2002, where he addressed the critical liquidity challenges faced by the company and led the entry of a set of private equity investors that helped re-brand the company. In 2007, he joined Cairn India ltd, where he guided the financing of the country's largest greenfield upstream onshore oil and gas development project which was the first large project of its size and complexity in India. He was also President and CFO, and a Member of the Executive Committee, at Ranbaxy Laboratories Ltd between 2011 and 2015, where he helped the company sustain itself through its most challenging times and played a critical role in the process leading to the merger of the company with Sun Pharma, later leading the integration of businesses and processes of the merged entity post-merger. In all the organisations where he has held key managerial positions, he has focused on enhancing stakeholder value while ensuring superior systems and processes that respect good governance practices.
Since 2015 he has engaged in certain specific management consultancy services, including business structuring and planning, management of growth situations, management of crisis situations through cash flow monitoring, prioritisation of operational requirements and bank relationship management, financing of working capital and establishment of Risk Management processes in multi-business and multi-regional organisations, business and financial process integration for existing organisations as well as for merging entities.
Mr Joe Sim is the Group Chief Operating Office of IHH Healthcare Berhad.
Mr Sim has served Parkway Pantai Limited since June 2017 as the Chief Executive Officer of Malaysia Operations Division, Parkway Pantai. He provides strategic direction and leadership for Parkway Pantai’s integrated healthcare businesses in Malaysia, which includes a network of 15 Gleneagles and Pantai hospitals and ancillary services such as Pantai Integrated Rehab and Pantai Premier Pathology.
Mr Sim has more than 20 years’ experience in the healthcare industry and was the winner of the Leading CEO Award by Singapore Human Resources Institute in 2014. Prior to joining Parkway Pantai, he was Group Deputy Chief Executive of National University Healthcare System in Singapore, where he had also served as Chief Operating Officer and Chief Executive Officer of National University Hospital. He also held the roles of Chief Corporate Development Officer, acting Chief Information Officer and acting Chief Executive Office for new ventures with the National Healthcare Group in Singapore.
Mr Sim began his career with the Singapore Administrative Service, building up a robust portfolio at the Ministry of Finance, Community Development Council and Ministry of Defence. In 2000, he founded a company that developed business-to-business trading hubs before joining the private sector where he was responsible for developing thought leadership, concepts and innovations on next-generation revenue agency for Accenture. Between 2008 and 2015, Mr Sim was also an adjunct lecturer at Nanyang Business School, during which he was recognised with a Teacher of the Year Award.
Mr Sim graduated with First Class Honours in Bachelor of Arts in Electronic and Information Science from Cambridge University and holds a Master in Public Administration from Harvard University.
Mr. Joerg Ayrle was appointed the Group Chief Financial Officer of IHH Healthcare Berhad (IHH) on 1 February 2021. With a wealth of international experience from United States, Germany, Singapore, China and Thailand, he will be responsible for providing financial leadership and strategic guidance for IHH and its operations and the business plan development. In his role, Joerg will ensure effective management of resources, safeguard shareholders’ interests and steer financial and management reporting, treasury, tax and investor relations functions and support the companies M&A activities.
Prior to joining IHH, Mr. Ayrle was the GCFO of Thai Union Group and steered the Company’s financial transformation journey, winning multiple awards including Best CFO Asia by Corporate Treasurer in 2016.
He also had a successful career with tech giants Osram and Siemens. Most notably, he was Chief Financial Officer & Treasurer of Osram Sylvania, USA, and Managing Director of Corporate Finance Mergers, Acquisitions & Post Closing (ASIA) for Siemens, China.
Masters of Business Administration major in Finance & Controlling, Marketing, Finance-Mathematics, University of Augsburg, Germany
Advisory Professor, Tongji University, Shanghai/China
Certified Fellow at the Institute of Directors, Thailand
Dr Kelvin Loh is the Managing Director and Chief Executive Officer (CEO) of IHH Healthcare, where he leads a team of 65,000 employees to realise IHH’s vision to be the world’s most trusted healthcare services network.
With a clear focus on trust and transparency, Dr Loh sets the strategic direction for the sustainable growth of IHH’s global network which today comprises 80 hospitals and more than 15,000 licensed beds in 10 countries. Our reputable and well-recognised brands including Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Pantai, and Parkway are united under a common purpose - to touch lives and transform care.
Since taking the helm of the company on 1 July 2019 as CEO (Designate) and Executive Director, before becoming the Managing Director and CEO on 1 January 2020, Dr Loh has focused on building long-term relationships with our patients, employees, partners and other stakeholders based on trust. Leveraging his extensive experience in leading large healthcare businesses, managing hospital operations and developing people, he has steered the company through the COVID-19 crisis, enabling it to achieve business resilience during the pandemic.
Prior to IHH, Dr Loh was CEO of Columbia Asia Group where he oversaw its healthcare business comprising 28 hospitals across four countries in Asia since 2017, deepening his familiarity with the healthcare operating context in different countries.
Dr Loh holds a Bachelor of Medicine and Bachelor of Surgery and a Master of Business Administration from the National University of Singapore. He spent the early years of his career as a general physician, until a growing passion for healthcare systems improvement launched him on the management track in the public healthcare sector. In 2008, he joined IHH Healthcare where he served nine years in numerous senior management roles, including as Chief Executive Officer of Singapore Operations in charge of the group’s integrated healthcare businesses in Singapore.
An expert in lean management systems, Dr Loh was previously a member of Singapore's National Expert Advisory Panel for Healthcare Productivity and Advisor to the Asia Productivity Organisation. He was also a Visiting Lecturer for the Master of Public Health and Master of Business Administration programmes at the National University of Singapore.
Ms. Shailaja Chandra’s has been a member of the Indian Administrative Service and her last two appointments were as permanent Secretary in the Health Ministry and later as Chief Secretary, Delhi - the only woman to have held this position. Having worked in the central Ministries of Defence, Power and Health and the governments of Delhi, Manipur, Goa and the Andaman & Nicobar islands she brings a width of cross-cutting experience involving both policy making and citizens issues.
In Health Ministry for 7 years continuously she handled the budgets and proposals needing Government approval concerning AIIMS, PGI, Chandigarh, ICMR, NIMHANS and the erstwhile MCI. As Chief Secretary Delhi she was Chairman of the Governing Bodies of the Liver & Biliary Institute, the Institute for Human Behaviour, & Allied Sciences and ex-officio Chairman of the Indraprastha Apollo hospital board.
Post – retirement she has been Chairman of the Pubic Grievances Commission and later the first Executive Director of the National Population Stabilisation Fund, Chairman of the Governing Bodies of two renowned Delhi University colleges, Chairman of the Delhi Library Board under the Ministry of Culture and has been associated with the management of 3 apex level NGOs. From 2018 to 2021, she was appointed by the National Green Tribunal to monitor the abatement of pollution in the River Yamuna and the completion of 10 biodiversity projects for rejuvenating the river.
Since 2012 she has also been an independent director on the Boards of several Indian Companies.
Shailaja is a prolific writer having written an anthology of articles, authored 2 Reports commissioned by the Health Ministry and the Delhi Government, published articles in peer reviewed journals and contributed book chapters as requested by OECD and the WHO.She continues to write OPEDs on public policy.
The Institute of Advanced Studies at Nantes, France and the Shiv Nadar University awarded her two prestigious academic fellowships. In 2021, she was conferred the honorary degree of Doctor of Literature by the Trans Disciplinary University in Bengaluru.
Ms. Suvalaxmi Chakraborty, has over 32 years of experience in the field of financial services and banking. She has rich exposure to various facets of banking, including Corporate Banking, Treasury Management, Asset Liability Management, Corporate Risk Management, Micro-Banking and Agri business. She has also featured in the Fortune India List of 50 most powerful women in business.
Ms. Chakraborty, currently, is the Founder, CEO & MD of FinReach Solutions Private Ltd., set up by a few investors with a view to facilitate credit access for MSMEs. At FinReach, she is responsible to set up the business, technology platform, operationalize the entity and run the day to day operations. She is a Non Executive Director of Espandere Advisors Pvt. Ltd., providing Business and Transaction Advisory services in Banking & Finance, Agriculture & Rural, Infrastructure and Manufacturing Sector. She has also worked as Advisor, Fullerton India Credit Company Ltd., a 100% step down subsidiary of Temasek Holdings (Pte) Ltd, Singapore.
Ms. Chakraborty held several positions at ICICI Ltd. and ICICI Bank between 1989 and 2006, including General Manager for Corporate Banking and Country Head of Rural, Micro-banking and Agri Business.
She launched and ran the commercial banking business of Barclays Bank in India from 2007 to 2010, after which she was Chief-Executive Office for the Indian operations of State Bank of Mauritius from 2010 to 2013.
Currently she serves as an Independent Director for SRL Diagnostics and nominee director in Kaleidofin Private Ltd. She has held the position of Independent/ Nominee Director in the past in Magma HDI General Insurance Company Ltd., Caspian Impact Investments Pvt Ltd., IIFL home Finance Ltd. and North East Small Finance Bank Ltd.
She is a Chartered Accountant and has a B. Com. (Hons) degree from Calcutta University and in 1999 completed the Financial Investment Technology Program of the Berkeley Program in Finance at HAAS School of Business at University of California, Berkeley, California. In 2002 she participated in the Leading Change and Organizational Renewal Program at the Graduate School of Business, Stanford University, California, and she has also participated in the 'Women on Corporate Boards' initiative initiated by FICCI Centre for Corporate Governance.
Appointed to the Board of IHH Healthcare Berhad (IHH) in 2019, Mr Takeshi Saito was an alternate director to Mr Satoshi Tanaka and Mr Koji Nagatomi, former Directors of IHH, between June 2015 and March 2019. He also serves on the Boards of a few IHH subsidiaries. Mr Saito currently serves as Chief Executive Officer (CEO) of MBK Healthcare Management Pte Ltd (MHM), a wholly-owned subsidiary of Mitsui & Co., Ltd (Mitsui) based in Singapore, which manages the healthcare assets within the portfolio of Mitsui.
Preceding his appointment as CEO of MHM, he served as General Manager of Healthcare Business 1st Department in Healthcare Business Division of Mitsui. In 2017, he was an Executive Assistant to a Representative Director and Executive Vice President of Mitsui. Between 2015 and 2016, he was the General Manager of the Provider Network Department, Medical Healthcare Business Division 1, Consumer Service Business Unit of Mitsui and also sat on the Board and Executive Committee of Parkway Pantai Limited, a wholly-owned subsidiary of IHH, as an alternate director. In 2011, Mr Saito was seconded to Parkway Group Healthcare as Vice President of Strategic Planning, following his appointment as Director of the Medical Healthcare Business Department at Mitsui, where he led the investment in IHH.
Prior to this in 2007, Mr Saito was appointed Manager of the Strategic Planning/Business Development Department of the Life Science Division at Mitsui, which subsequently became the Medical Healthcare Division in 2008.
Academic / Professional Qualification(s)
Bachelor of Political Science, Keio University, Japan Master of Business Administration, Kellogg School of Management Northwestern University
The Securities and Exchange Board of India (“SEBI”) has by circular No. SEBI / HO / MIRSD / MIRSD_RTAMB / P / CIR / 2021 / 655 dated 3rd November, 2021 laid down common and simplified norms for processing shareholder’s service request by RTAs. The circular, effective from 1st January, 2022, also provides for mandatory furnishing of PAN, KYC details, nomination; freezing of folios without valid PAN, KYC details; compulsory linking of PAN and Aadhaar by shareholders in physical form, among others. Further, by Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/687 dated 14th December, 2021; SEBI has issued some clarifications to the circular dated 3rd November, 2021(collectively referred to as ‘the Circulars’).
It is in your interest to provide the details / documents. If already provided, please treat this communication for information purpose only.
Please submit the documents / details listed in the table below to KFin, (self-attested) at the following address:
Freezing of Folios without PAN, KYC details and Nomination
Folios wherein any one of the above mentioned documents / details are not available on or after 1st April, 2023, shall be frozen by KFin / the Company in terms of the Circulars. The frozen folios will be referred by KFin the Company to the administering authority under the Benami Transactions (Prohibitions) Act, 1988 and or Prevention of Money Laundering Act, 2002, if they continue to remain frozen as on 31st December, 2025.
Compulsory linking of PAN and Aadhaar by all shareholders in physical mode
From 31st March, 2022 or any other date as may be specified by the Central Board of Direct Taxes (“CBDT”), KFin will accept only valid PANs and also verify that the PAN in the existing folios are valid; i.e. it is linked to the Aadhaar number of the shareholder. The folios wherein PAN is not valid as on the notified cut-off date of 31st March, 2022 or any other date as may be specified by the CBDT, will also be frozen.
In terms of the Circulars, w.e.f 1st January, 2022, KFin will not process any service request or complaint from shareholder(s)/claimant(s), unless PAN, KYC and Nomination documents/details are available.
English an Indo-European language belonging to the West Germanic branch; the official language of Britain and the United States and most of the commonwealth countries More (Definitions, Synonyms, Translation)